TP53 and prostate carcinoma: In prostate cancer, miR-340 was found to inhibit cell proliferation and metastasis by targeting the MDM3–p53 pathway, and to suppress the tumorigenic potential of prostate cancer cells by targeting the high-mobility group nucleosome-binding domain 5 [13, 20].